BLINCYTO Drug Profile

Summary for Tradename: BLINCYTO

High Confidence Patents:	16
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for BLINCYTO

Recent Clinical Trials for BLINCYTO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
Ho Joon Im	Phase 2
Goethe University	Phase 1/Phase 2

See all BLINCYTO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BLINCYTO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BLINCYTO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2024-11-26	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2034-02-07	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2034-04-07	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-07-25	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2036-08-10	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2032-04-30	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-12-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for BLINCYTO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2034-02-07	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-07-25	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2036-08-10	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-12-06	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2036-10-04	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-02-13	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557		2037-02-03	Patent claims search

International Patents for BLINCYTO

Country	Patent Number	Estimated Expiration
European Patent Office	1976886
World Intellectual Property Organization (WIPO)	2016179123
Israel	138857
Cuba	23252
Poland	2493503
World Intellectual Property Organization (WIPO)	2013120497
China	110294741

Supplementary Protection Certificates for BLINCYTO

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2016 00020	Denmark		PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151125
C 2016 013	Romania		PRODUCT NAME: BLINATUMOMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1047; DATE OF NATIONAL AUTHORISATFIRST AUTHORISATION IN EEA: 20151123 ION: 20151123; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1047; DATE OF
2016/021	Ireland		PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151123
C01691833/01	Switzerland		PRODUCT NAME: BLINATUMOMABUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 65654 25.02.2016
122016000028	Germany		PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151123
1690016-9	Sweden		PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151123
93067	Luxembourg		PRODUCT NAME: BLINATUMOMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BLINCYTO); FIRST REGISTRATION DATE: 20151125

Market Dynamics and Financial Trajectory for BLINCYTO (blinatumomab)

Last updated: February 19, 2026

What is BLINCYTO and its Approved Indications?

BLINCYTO (blinatumomab) is a bispecific T-cell engager (BiTE) antibody construct developed by Amgen. It targets CD19 on B-cell malignancies and CD3 on T cells, facilitating targeted immune response.

Initially approved by the U.S. FDA in December 2014 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), BLINCYTO's label expanded in 2017 for minimal residual disease (MRD)-positive B-cell ALL in adult patients. Its regulatory path includes approvals in Europe, Japan, and other markets.

Market Size and Growth Drivers

Global Hematologic Malignancies Market (2022–2027)

Year	Market Value (USD billion)	Compound Annual Growth Rate (CAGR)
2022	15.2	7.0%
2023	16.3
2024	17.5
2025	18.8
2026	20.2	7.2% estimate

The subset of B-cell malignancies, particularly ALL, accounts for approximately 25% of hematologic cancers, translating into a targeted market segment exceeding USD 4 billion globally in 2023. The driver is increasing prevalence, with an estimated 6-8 cases per 1 million population annually worldwide.

Key Factors Influencing Growth

• Limited Off-the-Shelf Options: BLINCYTO's unique mechanism of action positions it as a desirable option for relapsed/refractory cases.
• Regulatory Milestones: Approval expansions, including in pediatric populations, can stimulate adoption.
• Competing Treatments: CAR T-cell therapies like Kymriah (Novartis) and Yescarta (Gilead) face competition from BLINCYTO, which has a shorter manufacturing timeline and established billing codes.

Revenue Trajectory and Sales Trends

Historical Sales Data

Year	Global Sales (USD millions)	Year-over-Year Growth	Notes
2017	100	—	Initial launch phase
2018	250	150%	Expanded indications
2019	380	52%	Increased physician familiarity
2020	500	31.5%	Pre-pandemic growth
2021	620	24%	Continued uptake
2022	720	16.1%	Pandemic slowdown impact

Projected Sales for 2023–2025

Analyst consensus predicts a CAGR of approximately 15–20% over the next three years, driven by:

• Broadened indication approvals
• Penetration into earlier lines of therapy
• Physician preference over CAR T-cell therapy in specific patient subsets due to logistical considerations

Year	Projected Sales (USD millions)	Notes
2023	850	Uptake expansion
2024	1,020	Greater access and POC positioning
2025	1,220	Increased acceptance

Competitive Landscape and Market Access

Key Competitors

• Kymriah (tisagenlecleucel): Approved for pediatric and adult ALL; high manufacturing costs; longer lead time.
• Yescarta (axicabtagene ciloleucel): Approved for relapsed/refractory large B-cell lymphoma; similar manufacturing challenges to Kymriah.
• Other BiTEs: Amgen's own investigational drugs; emerging therapies in early stages.

Market Access Challenges

• Reimbursement rates vary globally, with high costs limiting outpatient usage.
• Facility Requirements: Specialized manufacturing and administration settings increase logistical hurdles.
• Toxicity Management: Cytokine release syndrome and neurotoxicity require specialized management, impacting uptake.

Regulatory and Clinical Development Milestones

• FDA Fast Track Designation: For certain indications, expediting approval.
• Orphan Drug Status: For pediatric ALL, providing market exclusivity until at least 2025.
• Upcoming Trials: Investigations into first-line therapy and combination regimens may extend the drug's use and revenue base.

Financial Impact of Patent and Exclusivity

• Patent Timeline: Expiring in 2029, with patent extensions under pediatric exclusivity.
• Generic Competition: Not expected before 2029, given biological complexity and regulatory protections.

Market Penetration Strategies

• Expanding Indications: Including frontline treatments and MRD-positive cases.
• Combination Therapy Trials: With chemotherapy, checkpoint inhibitors, and other immunotherapies.
• Geographic Expansion: Entering Asian markets where B-cell malignancies show rising incidence.

Risks and Uncertainties

• Market Competition: From CAR T-cell therapies and novel BiTE agents.
• Reimbursement Pressures: Cost containment measures may restrict adoption.
• Regulatory Shifts: Non-approvals or label restrictions could reduce sales.
• Clinical Success of Competitors: Emergent data from trials on alternative therapies could change the landscape.

Key Takeaways

• BLINCYTO's market is expanding with a forecasted CAGR of 15–20%, aided by broadening indications and increasing physician familiarity.
• Sales growth remains robust, with projected revenues surpassing USD 1 billion by 2024.
• Competition comes primarily from CAR T-cell therapies, but BLINCYTO benefits from manufacturing simplicity and logistical advantages.
• Market access and reimbursement will influence long-term revenue, especially outside North America and Europe.

Frequently Asked Questions

1. How does BLINCYTO compare to CAR T-cell therapies?
BLINCYTO offers an off-the-shelf alternative with quicker administration. It has a different safety profile and typically lower cost, influencing its position in treatment algorithms.

2. What are the primary factors restricting BLINCYTO’s growth?
Toxicity management, reimbursement challenges, and competition from other immunotherapies constrain growth.

3. Are there plans for expanding BLINCYTO’s indications?
Yes, clinical trials exploring earlier lines of therapy, combinations, and pediatric use are ongoing.

4. When is patent expiration, and what are the implications?
Patents expire in 2029, after which biosimilar entry is possible, potentially reducing prices and revenues.

5. What is the long-term financial outlook for BLINCYTO?
Projections indicate sustained growth through 2025, with revenues potentially stabilizing or declining post-2029 due to biosimilar competition unless new indications or formulations are approved.

---

References

[1] Amgen Inc. (2023). BLINCYTO (blinatumomab) prescribing information.
[2] Grand View Research. (2023). Hematologic malignancies market analysis.
[3] Evaluate Pharma. (2023). Oncology drug revenue database.
[4] European Medicines Agency. (2014). Approval details for BLINCYTO.
[5] IQVIA. (2023). Healthcare market intelligence data.